TrialNet’s Teplizumab (anti-CD3) Prevention Study shows that the drug can delay type 1 diabetes a median of 2 years in children and adults at high risk.

The study’s findings were presented on June 9 at the 2019 American Diabetes Association’s 79th Scientific Sessions and published in the New England Journal of Medicine.

Type 1 diabetes is an autoimmune disease that occurs when the body's immune system attacks and destroys insulin-producing beta cells in the pancreas, causing abnormal blood glucose (sugar) levels. Teplizumab is an immunotherapy drug designed to interfere with the body’s immune destruction of its own beta cells.

While previous studies showed teplizumab prolonged insulin production in people recently diagnosed, this is the first study to test it in people at high risk for the disease who do not yet have a T1D diagnosis.

Learn more…